Kyle Carver's most recent trade in Evommune Inc. was a trade of 13,290 Common Stock done at an average price of $17.8 . Disclosure was reported to the exchange on Dec. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evommune Inc | Kyle Carver | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.84 per share. | 09 Dec 2025 | 13,290 | 62,510 | - | 17.8 | 237,094 | Common Stock |
| Evommune Inc | Kyle Carver | Chief Financial Officer | 07 Nov 2025 | 25,000 | 0 | - | - | Series B Preferred Stock | ||
| Evommune Inc | Kyle Carver | Chief Financial Officer | 07 Nov 2025 | 3,175 | 75,800 | - | - | Common Stock | ||
| Evommune Inc | Kyle Carver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2025 | 279,408 | 279,408 | - | - | Employee Stock Option (Right to Buy) |